Atea Pharmaceuticals (AVIR) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free AVIR Stock Alerts $3.69 -0.01 (-0.27%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBML Capital Management LLC Grows Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)marketbeat.com - April 24 at 5:18 AMStonepine Capital Management LLC Trims Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)marketbeat.com - April 9 at 9:43 PMAtea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patientsglobenewswire.com - March 27 at 7:00 AMAtea Pharmaceuticals, Inc.edition.cnn.com - March 21 at 3:16 AMAVIR Apr 2024 2.500 callfinance.yahoo.com - March 16 at 9:54 AMFmr LLC Cuts Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)marketbeat.com - March 5 at 6:27 AMAVIR Mar 2024 7.500 callfinance.yahoo.com - March 3 at 7:34 PMAtea Pharmaceuticals: Balancing Promising Prospects with Clinical and Regulatory Risksmarkets.businessinsider.com - March 1 at 3:05 PMAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 1 at 12:01 AMAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 29 at 2:00 PMAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Down 57.4% in Februarymarketbeat.com - February 29 at 6:05 AMRecap: Atea Pharmaceuticals Q4 Earningsbenzinga.com - February 28 at 8:14 PMAtea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Resultsfinance.yahoo.com - February 28 at 8:14 PMAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - February 28 at 4:05 PMAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024finance.yahoo.com - February 21 at 8:06 AMAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024globenewswire.com - February 21 at 7:00 AMSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Atea Pharmaceuticals, Inc. (AVIR) and Encourages Investors to Contact the Firmstockhouse.com - February 13 at 9:29 AMAtea Pharmaceuticals, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.66) Per Share (NASDAQ:AVIR)marketbeat.com - February 7 at 8:07 AMAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) CAO Sells $47,911.68 in Stockmarketbeat.com - February 3 at 12:22 AMShort Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Expands By 7.1%marketbeat.com - January 15 at 5:48 PMAtea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Studyfinance.yahoo.com - January 10 at 12:55 PMAtea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacymsn.com - January 9 at 3:36 PMAtea gains after mid-stage data for lead asset in Hepatitis Cmsn.com - January 9 at 3:36 PMAtea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19finance.yahoo.com - January 8 at 6:17 PMAtea Pharmaceuticals Inc Ordinary Sharesmorningstar.com - January 6 at 11:28 PMAtea Pharmaceuticals Inc Ordinary Sharesmorningstar.com - January 6 at 11:28 PMAtea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 7:52 AMBML Capital Management LLC Grows Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)marketbeat.com - January 1 at 8:08 AMAtea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023finance.yahoo.com - November 13 at 8:20 AMAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 9 at 7:57 PMQ3 2023 Atea Pharmaceuticals Inc Earnings Callfinance.yahoo.com - November 9 at 9:56 AMAtea Pharmaceuticals GAAP EPS of -$0.40msn.com - November 8 at 7:05 PMAtea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 8 at 7:05 PMAtea Pharmaceuticals Announces Participation at Upcoming Investor Conferencesfinance.yahoo.com - November 8 at 8:59 AMAtea Pharmaceuticals Q3 2023 Earnings Previewmsn.com - November 8 at 1:04 AMAtea Pharmaceuticals's Earnings Outlookbenzinga.com - November 7 at 3:03 PMAtea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023finance.yahoo.com - November 2 at 8:00 AMAtea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023finance.yahoo.com - November 1 at 10:32 AMAuour Investments LLC Acquires New Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)marketbeat.com - September 15 at 11:15 AMMartingale Asset Management L P Sells 176,185 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)marketbeat.com - September 8 at 5:28 AMAtea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conferencefinance.yahoo.com - September 6 at 8:16 AMNew York Life Investment Management LLC Has $487,000 Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)marketbeat.com - August 15 at 5:45 AMFederated Hermes Inc. Has $6.83 Million Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)marketbeat.com - August 14 at 5:37 AMQ3 2023 EPS Estimates for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Increased by William Blairmarketbeat.com - August 14 at 2:46 AMLeerink Partnrs Comments on Atea Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:AVIR)marketbeat.com - August 11 at 9:44 AMJP Morgan Downgrades Atea Pharmaceuticals (AVIR)msn.com - August 11 at 12:18 AMQ2 2023 Atea Pharmaceuticals Inc Earnings Callfinance.yahoo.com - August 9 at 7:51 AMAtea Pharmaceuticals GAAP EPS of -$0.34 beats by $0.15msn.com - August 8 at 9:42 PMAtea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 8 at 4:42 PMEarnings Preview For Atea Pharmaceuticalsbenzinga.com - August 8 at 11:21 AM Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). AVIR Media Mentions By Week AVIR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVIR News Sentiment▼1.540.38▲Average Medical News Sentiment AVIR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVIR Articles This Week▼11▲AVIR Articles Average Week Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Enanta Pharmaceuticals News Terns Pharmaceuticals News ESSA Pharma News Inozyme Pharma News Neoleukin Therapeutics News Verrica Pharmaceuticals News CorMedix News Ventyx Biosciences News Mereo BioPharma Group News Akebia Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVIR) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
